- Christian Kanstrup steps down as CEO of Evaxion (EVAX, Financial), a clinical-stage TechBio company.
- Dr. Birgitte Rønø appointed interim CEO while the company searches for a permanent replacement.
- Thomas Schmidt becomes permanent CFO to strengthen financial leadership during the transition.
Evaxion A/S (NASDAQ: EVAX), a pioneering TechBio company focusing on AI-driven vaccine development, has announced key changes in its executive management team to maximize the potential of its AI-Immunology™ platform and extensive pipeline. CEO Christian Kanstrup has resigned, and the Board of Directors is actively searching for a new CEO who can lead the company’s growth and accelerate value through strategic business partnerships.
Dr. Birgitte Rønø, who has been Evaxion’s Chief Scientific Officer since 2017 and joined the Executive Management in 2021, has been appointed as the interim CEO. Her appointment is aimed at ensuring leadership continuity as the company transitions and seeks new strategic leadership focused on business development and partnership capabilities.
Thomas Schmidt, who has served as the interim Chief Financial Officer since November 2024, has now been appointed as the permanent CFO. His expertise in financial acumen and capital markets is expected to enhance the company’s strategic direction, especially during this transitional phase.
These management adjustments are part of Evaxion's strategic plan to shift focus from research and development to more aggressive commercialization and partnership strategies, leveraging over 17 years of platform development. The board’s current CEO search emphasizes candidates with strong business development acumen and transformational leadership qualities vital for driving future strategic partnerships.
